Pancreatic Cancer Research

ResearcherYamaguchi UniversityNo recent work listed

Isao Sakaida

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8365-7547; OpenAlex author ID A5039682429, A5082111082. Sources: OpenAlex.

Their work

Papers
17 (first author 0, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
31
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: 2 papers · 2014: 2 papers · 2015: none · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers

Papers 17

  1. Correction: Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox. Last author DOI 10.1186/s12885-023-11091-y↗
  2. Retraction Note: Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox. Last author DOI 10.1186/s12885-023-11677-6↗
  3. CA19-9 in Combination with Methylated HOXA1 and SST Is Useful to Diagnose Stage I Pancreatic Cancer. Co-author DOI 10.1159/000527342↗
  4. Combination of CA19-9 and Blood Free-Circulating Methylated RUNX3 May Be Useful to Diagnose Stage I Pancreatic Cancer. Co-author DOI 10.1159/000511940↗
  5. Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox. Last author DOI 10.1186/s12885-020-07167-8↗
  6. Successful endoscopic ultrasound-guided gallbladder drainage through the mesh of a duodenal stent for cholecystitis in a patient with pancreatic cancer. Last author DOI 10.1111/den.13409↗
  7. [Five Cases of Ten-Year Survival after Surgical Treatment of Pancreatic Cancer in Yamaguchi Prefecture]. Co-author PMID 32156955↗
  8. Deferasirox, an oral iron chelator, with gemcitabine synergistically inhibits pancreatic cancer cell growth in vitro and in vivo. Last author DOI 10.18632/oncotarget.25421↗
  9. Heat Shock Protein 27 Expression in EUS-FNA Samples Can Predict Gemcitabine Sensitivity in Pancreatic Cancer. Last author DOI 10.21873/invivo.11286↗
  10. Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo. Last author DOI 10.1186/s12885-016-2744-9↗
  11. Active hexose-correlated compound down-regulates HSP27 of pancreatic cancer cells, and helps the cytotoxic effect of gemcitabine. Co-author PMID 24403454↗
  12. Active hexose-correlated compound down-regulates sex-determining region Y-box 2 of pancreatic cancer cells. Co-author PMID 25202061↗
  13. TWIST1 hypermethylation is observed in pancreatic cancer. Last author DOI 10.3892/br.2012.25↗
  14. Human pancreatic cancer cells with acquired gemcitabine resistance exhibit significant up-regulation of peroxiredoxin-2 compared to sensitive parental cells. Co-author PMID 24222118↗
  15. Heat-shock protein 27 plays the key role in gemcitabine-resistance of pancreatic cancer cells. Co-author PMID 22641665↗
  16. KNK437 downregulates heat shock protein 27 of pancreatic cancer cells and enhances the cytotoxic effect of gemcitabine. Co-author DOI 10.1159/000321019↗
  17. Proteomic differential display analysis for TS-1-resistant and -sensitive pancreatic cancer cells using two-dimensional gel electrophoresis and mass spectromet… Co-author PMID 21737628↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Taro Takami · 7 shared papers, 2016–2023 · strength 0.83
  2. Takahiro Yamasaki · 7 shared papers, 2016–2023 · strength 0.83
  3. Hirofumi Harima · 6 shared papers, 2016–2023 · strength 0.76
  4. Shogo Amano · 6 shared papers, 2018–2023 · strength 0.75
  5. Shuhei Shinoda · 6 shared papers, 2016–2023 · strength 0.69
  6. Shigeyuki Suenaga · 7 shared papers, 2012–2022 · strength 0.47
  7. Hiroto Matsui Matsui · 3 shared papers, 2019–2022 · strength 0.31
  8. Yutaka Suehiro · 3 shared papers, 2013–2022 · strength 0.28
  9. Yuko Fujimoto · 2 shared papers, 2021–2022 · strength 0.23
  10. Kazuyuki Nakamura · 6 shared papers, 2011–2014 · strength 0.20
  11. Yasuhiro Kuramitsu · 6 shared papers, 2011–2014 · strength 0.20
  12. Hiroaki Nagano · 2 shared papers, 2019–2022 · strength 0.20
  13. Manabu Sen-yo · 2 shared papers, 2013–2018 · strength 0.14
  14. Yoshihiko Maehara · 4 shared papers, 2011–2014 · strength 0.14
  15. Kaori Hamamoto · 1 shared paper, 2022 · strength 0.12
  16. Keiko Shinjo · 1 shared paper, 2022 · strength 0.12
  17. Yutaka Kondo · 1 shared paper, 2022 · strength 0.12
  18. Hiroaki Nagano · 1 shared paper, 2021 · strength 0.11
  19. Yufeng Wang · 3 shared papers, 2012–2014 · strength 0.10
  20. Michitaka Kawano · 1 shared paper, 2018 · strength 0.09
  21. Kumiko Taba · 3 shared papers, 2011–2012 · strength 0.08
  22. Shomei Ryozawa · 3 shared papers, 2011–2012 · strength 0.08
  23. Tomio Ueno · 1 shared paper, 2019 · strength 0.08
  24. Yoshitaro Shindo · 1 shared paper, 2019 · strength 0.08
  25. Masahiro Tanabe · 1 shared paper, 2019 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.